Ganglioside-exposed dendritic cells inhibit T-cell effector function by promoting regulatory cell activity

Abstract

Summary Tumour pathogenesis is characterized by an immunosuppressive microenvironment that limits the development of effective tumour‐specific immune responses. This is in part the result of tumour‐dependent recruitment and activation of regulatory cells, such as myeloid‐derived suppressor cells and regulatory T cells in the tumour microenvironment and draining lymph nodes. Shedding of gangliosides by tumour cells has immunomodulatory properties, suggesting that gangliosides may be a critical factor in initiating an immunosuppressive microenvironment. To better define the immunomodulatory properties of gangliosides on antigen‐specific T‐cell activation and development we have developed an in vitro system using ganglioside‐treated murine bone‐marrow‐derived dendritic cells to prime and activate antigen‐specific CD4+ T cells from AND T‐cell receptor transgenic mice. Using this system, ganglioside treatment promotes the development of a dendritic cell population characterized by decreased CD86 (B7‐2) expression, and decreased interleukin‐12 and interleukin‐6 production. When these cells are used as antigen‐presenting cells, CD4 T cells are primed to proliferate normally, but have a defect in T helper (Th) effector cell development. This defect in Th effector cell responses is associated with the development of regulatory T‐cell activity that can suppress the activation of previously primed Th effector cells in a contact‐dependent manner. In total, these data suggest that ganglioside‐exposed dendritic cells promote regulatory T‐cell activity that may have long‐lasting effects on the development of tumour‐specific immune responses.

Sphingolipid and Glycosphingolipid Metabolic Pathways in the Era of Sphingolipidomics

“… 23 , 485 The complete balance sheet for sphingolipids additionally includes uptake of sphingolipids from exogenous sources (such as albumin and lipoproteins) 486 , 487 and losses by efflux,( 488 ) lipoprotein secretion, 354 , 489 and shedding of membrane vesicles containing sphingolipids. ( 490 )…”

Meeting report: Regulatory myeloid cells

“…Dr. Stephan Ladisch described the capacity of lipid-raft associated ganglosides, which can be shed by tumors, to suppress immune function and promote tumor growth [4]. Tumors deficient in GM3/GM2 synthase impaired tumor growth and were associated with decreased MDSCs and increase in CD8+ T cells and NK cells.…”

The Sweet Side of Immune Evasion: Role of Glycans in the Mechanisms of Cancer Progression

“…Besides its effects on cytotoxic T cells, tumor-derived sialoglycans are also able to dampen DC functions ( 96 – 100 ). Studies have shown that tumor-derived sialogangliosides inhibit the upregulation of co-stimulatory molecules (CD80/CD86) as well as IL-12 production by DCs, thus impairing T cell effector lymphocyte activation ( 101 ). This immunosuppressive effect is thought to be elicited by the interaction of highly sialylated tumor antigens with the siglec receptors expressed by DCs ( 102 , 103 ).…”